Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 73 of 73 entries
View as:

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Phase: N/A Priority: Normal
NCT ID: NCT04866056 Org: User:
Start: 09/30/21 End: 06/10/22 Due: 06/10/23

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT04312594 Org: User:
Start: 09/08/20 End: 06/09/22 Due: 06/09/23

Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

Phase: N/A Priority: Normal
NCT ID: NCT03886415 Org: User:
Start: 01/08/19 End: 02/02/21 Due: 02/02/22

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05978284 Org: User:
Start: 10/27/23 End: 10/31/25 Due: 10/31/26

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02870569 Org: User:
Start: 09/30/16 End: 12/31/18 Due: 12/31/19

Study of ZG005 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06927687 Org: User:
Start: 05/31/25 End: 06/30/27 Due: 06/30/28

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT06237413 Org: User:
Start: 08/10/23 End: 02/28/26 Due: 02/28/27

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02698111 Org: User:
Start: 02/08/17 End: 10/20/21 Due: 10/20/22

A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02489201 Org: User:
Start: 07/21/15 End: 10/29/20 Due: 10/29/21

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06592638 Org: User:
Start: 03/31/25 End: 06/30/27 Due: 06/30/28

Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis

Phase: N/A Priority: Normal
NCT ID: NCT04459871 Org: User:
Start: 11/11/19 End: 10/20/21 Due: 10/20/22

Study of ZG0895.HCl in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05877664 Org: User:
Start: 08/08/23 End: 06/30/26 Due: 06/30/27

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04964284 Org: User:
Start: 10/06/21 End: 12/31/24 Due: 12/31/25

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT06239298 Org: User:
Start: 05/10/24 End: 05/31/26 Due: 05/31/27

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06283719 Org: User:
Start: 09/02/24 End: 04/30/26 Due: 04/30/27

Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Phase: N/A Priority: Normal
NCT ID: NCT05051761 Org: User:
Start: 09/04/21 End: 12/27/23 Due: 12/27/24

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06558227 Org: User:
Start: 10/24/24 End: 10/31/26 Due: 10/31/27

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06193148 Org: User:
Start: 03/19/24 End: 06/18/24 Due: 06/18/25

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Phase: N/A Priority: Normal
NCT ID: NCT05861102 Org: User:
Start: 07/20/23 End: 07/31/25 Due: 07/31/26

A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04612699 Org: User:
Start: 03/11/21 End: 08/15/22 Due: 08/15/23

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06903377 Org: User:
Start: 04/30/25 End: 05/31/27 Due: 05/31/28

Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02489916 Org: User:
Start: 03/31/14 End: 12/31/15 Due: 12/31/16

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06883526 Org: User:
Start: 05/31/25 End: 05/31/27 Due: 05/31/28